EMA Authorised: Andembry (garadacimab) — CSL Behring GmbH

View source ↗

Summary

European Medicines Agency authorises Andembry (garadacimab) for hereditary angioedema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ANDEMBRY (garadacimab)

Snippet

Status: Authorised. Therapeutic area: Angioedemas, Hereditary. MAH: CSL Behring GmbH. Decision date: 09/07/2026